Table 1 Baseline characteristics
From: Predictors of positive response to cardiac resynchronization therapy
Patient characteristics | Baseline (n = 82) |
|---|---|
Age (yrs.) | 63.5 ± 10.5 |
Gender (male,%) | 65 (79.3) |
QRS duration (ms) | 174.8 ± 17.0 |
NYHA class III n (%) | 68 (82.9) |
Six minute walk test (m) | 300.8 ± 70.4 |
Diabetes n (%) | 9 (10.8) |
Hypertension n (%) | 66 (80.5) |
Paroxysmal AF n (%) | 28 (34.5) |
VT n (%) | 25 (30.5) |
CRT-D n (%) | 36 (43.9) |
LVEF (%) | 20.3 ± 6.5 |
LVEDD (mm) | 68.5 ± 9.7 |
LVESD (mm) | 61.9 ± 10.0 |
LVEDV (ml) | 220.6 ± 76.3 |
LVESV (ml) | 175.3 ± 69.8 |
LAV (ml) | 93.3 ± 28.5 |
Beta blockers n (%) | 77 (93.9) |
ACE-I n (%) | 61 (74.4) |
ARB n (%) | 16 (19.5) |
MRA n (%) | 70 (85.4) |
Diuretics n (%) | 68 (82.9) |
Amiodarone n (%) | 24 (29.3) |
Statin n (%) | 40 (48.8) |
Aspirin n (%) | 29 (35.4) |
Warfarin n (%) | 27 (32.9) |
Uric acid (μmol/l) | 426.3 ± 133.2 |